anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a plant fiber sponge with a wrinkle removing effect and a preparation method thereof. The plant fiber sponge is prepared by adding water in devilstongue fine powder, gingko and vegetable sponge. The plant fiber sponge adopts the devilstongue fine powder to serve a load base, adds the gingko and the vegetable sponge into the devilstongue fine powder, and has special effects including whitening, wrinkle removing, cutin removing and the like on human skins. The plant fiber sponge with the wrinkle removing effect ingeniously combines the tool function of sponge and the skin-care and health-care effects of the gingko and the vegetable sponge together and gives new position to the skin-care sponge. Addition of the gingko and the vegetable sponge enables use friction force to be increased to the sponge, the strength of devilstongue gel is improved, and the devilstongue fine powder load base further enables the skin-beautifying effect of the gingko and the vegetable sponge to be released continuously and slowly. The ingenious combination brings great convenience to a user. In addition, the plant fiber sponge with the wrinkle removing effect adopts natural substance as raw materials, can be naturally degraded through microorganism and has no damage to environment, the preparation method is simple, and production process has no pollution to the environment.
OBJECTIVE: To assess and compile the current level of evidence regarding successful surgical treatment of vesicovaginal fistulae and how these perioperative interventions affect anatomic, patient-centered, and adverse outcomes.
DATA SOURCES: PubMed and EMBASE were searched from inception through September 9, 2022.
METHODS OF STUDY SELECTION: This review included comparative studies (of any sample size) and single-group studies (1,000 or more participants) of primary or recurrent vesicovaginal fistula (ie, vesicovaginal fistula, urethrovaginal fistula, and bladder neck-vaginal fistula). We evaluated preintervention assessment or management, various techniques for intraoperative management, and postoperative management. Outcomes of interest included anatomic and objective outcomes (such as successful repair, fistula closure, urinary incontinence, recurrent fistula, perioperative complications) and subjective outcomes (such as voiding symptoms and quality of life). Abstracts and full-text articles were screened in duplicate, and study descriptions and findings were extracted into standardized extraction forms. Risk of bias was assessed independently by two investigators and adjudicated by a third. Study quality was summarized with standardized tools. We conducted random-effects model and restricted maximum-likelihood meta-analyses of relative risks when at least three studies compared similar interventions and reported similar outcome measures.
TABULATION, INTEGRATION, AND RESULTS: Forty-six studies met the inclusion criteria. Studies were categorized into 11 domains: 1) preoperative assessment, 2) preoperative and postoperative physical therapy, 3) route of surgery, 4) incorporation of a flap, 5) trimming, 6) layered closure, 7) intraoperative antibiotics, 8) fibrin glue, 9) fascial sling, 10) postoperative Foley catheter duration, and 11) quality of life. Although the strength of the data is insufficient, preoperative phenazopyridine, physical therapy, layered closure, and intraoperative antibiotics seemed to improve the rate of successful fistula repair. Route of surgery (vaginal vs abdominal laparotomy) was determined primarily by surgeon preference and showed no difference in successful fistula repair. In addition, use of interpositional flaps, trimming fistula edges, fibrin glue, and fascial sling did not show significant improvement in rates of fistula cure. Overall, quality-of-life scores improved postoperatively regardless of route of repair and use of interpositional flaps.
CONCLUSION: Our findings highlight the limited information available to guide evidence-based treatment of vesicovaginal fistula repair. Overall, high-quality evidence is lacking to provide guidelines; therefore, expert opinion remains the primary influence for fistula repair recommendations.
SYSTEMATIC REVIEW REGISTRATION: PROSPERO, CRD42021214948.
Syndactyly release aims to address skin deficits by resurfacing web spaces and sides of digits to allow independent digital motion while minimizing the risk of web creep and scar contractures. Conventional methods include the use of a dorsal and interdigitating flaps with full-thickness skin grafts. More recently, there have been several descriptions of "graftless" syndactyly release without skin grafts, thus avoiding a further (usually distant) donor site. However, the indications of when and when not to use these techniques remain unclear. In addition, the inevitable scarring from extra recruitment of local adjacent skin is perhaps underemphasized. In this article, we revisit the trilobed flap technique which serves to balance the amount of skin needed for resurfacing digits while minimizing local donor site scarring. The geometry and nuances of the flap inset are illustrated in detail to guide those embarking on this technique. The trilobed syndactyly release technique is a reproducible, safe, and reliable method for the release of simple syndactyly.
PROBLEM TO BE SOLVED: To provide the method for producing a composite silica microcapsule encapsulating a core substance such as an org. compd. or an inorg. compd. SOLUTION: A surfactant and a mixed soln. contg. a surfactant and the core substance and an assistant such as catalyst or surfactant, as required, previously added to water are added as a dispersed phase to a continuous phase obtained by incorporating tetraalkoxysilane as a reactant and an assistant such as catalyst added, as required, into a low-polarity org. solvent forming an interface with water to increase the mole ratio of water to surfactant, and the mixture is agitated to form a water-in-oil emulsion. Further, tetraalkoxysilane is hydrolyzed and polycondensed with the water-in-oil emulsion solubilizing water as a reaction field while adjusting the agitation to synthesize a silica microcapsule. Consequently, the core is encapsulated in the peripheral shell of the microcapsule and/or in the hollow part at the central part.
Diclofenac and misoprostol are primarily excreted by the kidney. Long-term administration of NSAIDs has resulted in renal toxicity. Correct volume status in dehydrated or hypovolemic patients prior to initiating diclofenac sodium and misoprostol delayed-release tablets. Monitor renal function, especially during concomitant use of ACE inhibitors or ARBs. Also, monitor renal function in patients with hepatic impairment. Avoid the use of diclofenac sodium and misoprostol delayed-release tablets in patients with advanced renal disease. If use cannot be avoided in patients with advanced renal disease, use the lowest dosage for the shortest duration, monitor the patient’s renal function and monitor for clinical signs of worsening renal function [ see Warnings and Precautions ( 5.7), Drug Interactions ( 7) and Clinical Pharmacology ( 12.3) ].
BACKGROUND/AIM: Indoleamine 2,3-dioxygenase 1 (IDO1) is a key enzyme in tryptophan metabolism and plays an important role in immunosuppression. The effects of IDO1 on tumor invasion and metastasis have been studied in several types of malignancies. However, the role of IDO1 in these steps in colorectal cancer (CRC) has not been elucidated. Therefore, we aimed to investigate the effects of IDO1 on invasion, migration, and epithelial-mesenchymal transition (EMT) in CRC cells.
MATERIALS AND METHODS: All experiments were performed using the DLD-1 colon cancer cell line that expresses IDO1. We conducted a scratch wound healing assay and Boyden chamber assay to investigate the impact of IDO1 on DLD-1 cell migration and invasion, respectively, in the presence and absence of the IDO1 inhibitor L-1-methyl-tryptophan (L-1-MT). Additionally, western blotting was performed to analyze alterations in the expression of EMT-related markers caused by L-1-MT.
RESULTS: High expression of IDO1 was confirmed in the cytoplasm of DLD-1 by immunofluorescence staining. In the scratch wound healing assay, the invasion ability of DLD-1 cells decreased to 62% after treatment with L-1-MT at 1,000 μM for 24 h. In the Boyden chamber assay, the migration of DLD-1 cells was suppressed by 85% after treatment with L-1-MT at 2,500 μM for 24 h. L-1-MT treatment increased the expression level of E-cadherin and decreased the expression levels of vimentin, Snail, and Slug.
CONCLUSION: IDO1 inhibition reduced the invasion and migration ability of IDO1-expressing DLD-1 colon cancer cells, which was accompanied by altered expression of EMT-related proteins. IDO1 could be a potential target for the treatment of advanced CRC.
The present invention relates to a group of new oligonucleotides sequences with human tumor necrosis factor α (TNF-α) inhibiting activity, which includes DNA sequences and RNA sequences. These oligonucleotides or aptamer can specifically be bound to TNF-α and inhibit the cytoxicity of TNF-α to L929 cells. Therefore, the aptamer of the present invention may be used to detect TNF-α and provide a therapeutic method for diseases related to the increasing level of TNF-α. Compared with other TNF antagonists such as monoclonal antibody and soluble receptor, the present invention has high specificity, high affinity, quick penetration to target tissue, rapid plasma clearance, and lower immunogenecity. Turthermore, it can be used repeatedly and keeps high concentration in target tissue and the like. It has the advantages of affinity and specificity similar to monoclonal antibodies and also has permeability and pharmacokinetics characteristics similar to small molecular polypeptide. The present invention also refers to derivative of the oligonucleotides sequence, including modified sequence. The present invention may further be manufactured as medicine for therapy and diagnosis of TNF-α related diseases.
Lymphoma is extremely sensitive to radiation and is a commonly used therapy. The major issue in application of local radiotherapy is the relative short duration of response and as a consequence is used mainly for palliation. Therefore novel therapies are needed to improve the outcome of patients with lymphomas. The potential specificity of the immune system to recognize and eliminate tumor cells is especially relevant in lymphoma. Immune responses are induced, coordinated and regulated by dendritic cells (DCs), the most potent antigen-presenting cells. Based on the central role of DCs in initiating immune responses, four vaccinations will be administered at intervals beginning two days after low dose radiation is given to the tumor site.
1. Technical Result Increase in treatment efficiency of the diseases caused by degeneration of neurotic cells and reduction of differentiation factor. 2. Essence A glial derived neurotrophic factor (GDNF) has been identified and isolated, genes encoding GDNF have been cloned and sequenced; vectors and host cells to produce GDNF, pharmaceutical compositions containing GDNF have been obtained. 3. Field of Application Medicine, neurology.    Figures: 28
The invention belongs to the field of daily care technology, and particularly relates to plant hair dye. The hair dye comprises following components by weight: 200-300 parts of fleece-flower root, 12-25 parts of nutgall, 15-35 parts of natural indigo, 12-17 parts of dahurian angelica root, 17-30 parts of talcum, 10-20 parts of rhizome of Chinese nardostachys, 20-28 parts of weeping willow and 500-1000 parts of water. The hair dye is made of natural plant components. The hair dye is harmless to human bodies, and is nontoxic, non-irritant and allergen-free. Original fresh and alive components of herbal essence are preserved. The hair dye can patch to hair discolored after color dyeing to obtain the same color. The hair dye forms powerful protective film on hairlines, has good repair function for damaged hair, and allows the hair to be natural, strong and glossy.
PURPOSE:To provide the process for producing the liposome which can concentrate the physiologically active material in the drugs to be included in the liposome up to a high concn. and high density without denaturing this material, thereby yielding the liposome of high capsulation efficiency and capsulation yield. CONSTITUTION:This process has a 1st stage of rotating a rotor 3 having a heat transfer surface 3a disposed in a vacuum chamber 2, supplying the liquid chemical contg. the physiologically active material into this vacuum chamber 2 and instantaneously heating the thin film of the liquid chemical to evaporate its moisture while forming this film on the heat transfer surface 3a by the rotating force of the rotor 3, thereby concentrating the liquid chemical to the high concn. and the high viscosity and a 2nd stage of adding and mixing a liposome forming lipid mixture with the concd. liquid chemical and subjecting the resulted mixture to a suspension treatment, thereby forming the liposome.
This research aims to validate and develop WC-based equations due to the estimation potential to assess body composition in the athletic, physically active and sedentary Colombian population. We will follow the standardized reporting guidelines of the Strengthening the Reporting of Observational Studies in Epidemiology-Nutritional Epidemiology (STROBE-nut). Stratified probability sampling techniques will be used. Participants of \>18 years old, residing in Medellín or its metropolitan area, with different physical activity levels, and that give consent to be evaluated by health professionals will be invited to participate. Anthropometry and DXA assessment will be carried out in the participants. Subsequently, validation of the RFM will be performed by comparing the estimation results with gold standard methods using correlation and agreement (Bland-Altman) analyses. Finally, several models will be developed to estimate fat mass and fat-free mass in the population subgroups (athletes, physically active individuals and sedentary people). The results of this research will improve professional practice in health, exercise and sports science.

The F20 project is developed by the Research Division of the Dynamical Business \& Science Society-DBSS International SAS with the support of University CES, University de Córdoba, University Distrital Francisco José de Caldas, Exercise \& Sport Nutrition Laboratory at Texas A\&M University, the R\&D department of ARTHROS IPS, Smart Fit, and IPS Diagnosticarte.
After dying with Brilliant Blue G (Brilliant Blue; Gender, Germany) with the help of Constellation 23-gauge vitrectomy system, the intervention of "peeling" was used to grasped ILM with end-gripping forceps. And the postoperative posture would be prone position in two weeks for all patients after the operation.
PURPOSE: To provide a comspn. consisting of an aq. dispersion prepd. by dispersing the vesicles of amphiphilic lipid. CONSTITUTION: This aq. dispersion consist of the aq. dispersion phase of the vesicles which are prepd. from the ionic or nonionic amphiphilic lipid (more preferably the polyglycerol deriv. expressed by the formula RO-[C3 H5 (OH)O]-nH, where R is, for example, a 12 to 18C fatty acid residue, n=2 to 6) associated with at least one stabilizing additives and internally contain aq. layers. This compsn. for cosmetics for taking care of the hair contains natural or synthetic essential oil in this aq. dispersion layer. Cosmetic and/or cosmetically active materials may be incorporated into the water phase in the vesiscles and/or the lipid phase of the vesicles. The smooth, the appearanece and the shape of the hair are improved by adding the essential oil.
BACKGROUND: Trypanosomatid parasites are a group of protozoans that cause devastating diseases that disproportionately affect developing countries. These protozoans have developed several mechanisms for adaptation to survive in the mammalian host, such as extensive expansion of multigene families enrolled in host-parasite interaction, adaptation to invade and modulate host cells, and the presence of aneuploidy and polyploidy. Two mechanisms might result in "complex" isolates, with more than two haplotypes being present in a single sample: multiplicity of infections (MOI) and polyploidy. We have developed and validated a methodology to identify multiclonal infections and polyploidy using whole genome sequencing reads, based on fluctuations in allelic read depth in heterozygous positions, which can be easily implemented in experiments sequencing genomes from one sample to larger population surveys.
RESULTS: The methodology estimates the complexity index (CI) of an isolate, and compares real samples with simulated clonal infections at individual and populational level, excluding regions with somy and gene copy number variation. It was primarily validated with simulated MOI and known polyploid isolates respectively from Leishmania and Trypanosoma cruzi. Then, the approach was used to assess the complexity of infection using genome wide SNP data from 497 trypanosomatid samples from four clades, L. donovani/L. infantum, L. braziliensis, T. cruzi and T. brucei providing an overview of multiclonal infection and polyploidy in these cultured parasites. We show that our method robustly detects complex infections in samples with at least 25x coverage, 100 heterozygous SNPs and where 5-10% of the reads correspond to the secondary clone. We find that relatively small proportions (≤ 7%) of cultured trypanosomatid isolates are complex.
CONCLUSIONS: The method can accurately identify polyploid isolates, and can identify multiclonal infections in scenarios with sufficient genome read coverage. We pack our method in a single R script that requires only a standard variant call format (VCF) file to run ( https://github.com/jaumlrc/Complex-Infections ). Our analyses indicate that multiclonality and polyploidy do occur in all clades, but not very frequently in cultured trypanosomatids. We caution that our estimates are lower bounds due to the limitations of current laboratory and bioinformatic methods.
In this study, patients with intracranial and extracranial arteriosclerosis were included. The experimental group received basic treatment and remote ischemic conditioning for 200mmHg to pressurize the upper arm of the healthy side for 5 minutes, relax for 5 minutes, and repeat 4 cycles. The control group received basic treatment and remote ischemic conditioning for 60mmHg to pressurize the upper arm of the healthy side for 5 minutes, relax for 5 minutes, and repeat 4 cycles. The dynamic cerebral autoregulation was measured before treatment, immediately after treatment, 6 hours after treatment and 24 hours after treatment in both groups. The investigators aimed to determine the effect of remote ischemic conditioning on the dynamic cerebral autoregulation in patients with intracranial and extracranial arteriosclerosis. The investigators hypothesized that remote ischemic conditioning would improve dynamic cerebral autoregulation in patients with intracranial and extracranial arteriosclerosis.
The invention provides an acetaminophen novel crystal form. Shown by a diffraction angle 2theta, the X-ray powder diffraction pattern of the acetaminophen novel crystal form has peaks at diffraction angles of 12.182 degrees, 15.610 degrees, 18.219 degrees, 20.421 degrees, 23.579 degrees, 24.501 degrees, 26.644 degrees and 36.949 degrees, wherein the error is +/-0.2 degree. The invention further provides a preparation method of the acetaminophen novel crystal form. The invention further provides a compound paracetamol and amantadine hydrochloride preparation. The acetaminophen novel crystal form provided by the invention has performances such as good stability, bioavailability, solubility, high dissolution rate, chemical stability and thermodynamic stability, and has a dissolution rate of over 90% within 30 minutes. Besides, when the acetaminophen novel crystal form provided by the invention is used for preparing the compound paracetamol and amantadine hydrochloride preparation, the compound paracetamol and amantadine hydrochloride preparation, for example a compound paracetamol and amantadine hydrochloride tablet has a dissolution rate of over 97%.
This research is a dietary intervention study designed to evaluate the effect of progressive changes in Zn intake on fatty acid metabolism and to correlate those changes with biomarkers of dyslipidemia and insulin resistance. The main objective is to validate plasma fatty acid metabolism as a biomarker of inadequate Zn intake in subjects consuming identical diets with specific Zn content. The relative sensitivity of some fatty acid enzyme activities will also be compared to the DNA strand breaks. In addition to the primary objectives, correlations in enzyme activity with changes in fat metabolism, namely circulating triglyceride and cholesterol, will be determined. This will enable the determination of the effect of a low Zn intake on various aspects of dyslipidemia. Similar correlational analyses will be performed with clinical measures of inflammation and insulin resistance.
This is a multicenter,open label, phase 2 trial to investigate the efficacy and safety of utidelone in combination with bevacizumab in the treatment of advanced breast cancer with brain metastases. Patients with HER2-negative advanced breast cancer who have received at least one prior anthracycline and one prior taxane or HER2-positive advanced breast cancer who have failed trastuzumab and pyrotinib, and with at least one measurable CNS lesion are eligible for the study.

This study includes 2 cohorts, and the Simon two-stage design are applied, respectively. A total of 48 patients with HER2-negative advanced breast cancer are included in cohort 1, and 52 patients with HER-2 positive patients are enrolled in cohort 2. Patients in both cohorts receive bevacizumab, 15mg/kg, day 1, and utidelone, 30mg/m2 (±10%), day 1-5 every 3-week cycle until disease progression or unmanageable toxicity. The primary endpoint is CNS-ORR according to the RECIST 1.1. The secondary endpoints include CNS-ORR according to RANO criteria, CNS-PFS assessed by investigator, extracranial ORR, extracranial PFS, OS, time to WBRT, quality of life and safety profile according to NCI-CTCAE 5.0.
PROBLEM TO BE SOLVED: To provide a hair cosmetic enabling free hair arrangement on the hair, having excellent setting power which holds the hair arrangement for a long time, imparting soft feeling to the hair, suppressing unnatural greasiness and gloss caused by an oil solution, and excellent in stability. SOLUTION: The hair cosmetic comprises the following components (A) to(D). (A) A clay mineral having oil-swelling property. (B) An oil which is liquid at 25 deg.C. (C) An oil which is pasty at 25 deg.C and has a melting point in a range of 30-60 deg.C. (D) A wax.
Cardiac amyloidosis is an infiltrative cardiomyopathy characterized by the extracellular deposition of amyloid fibrils within the myocardium. Beyond heart failure, patients with cardiac amyloidosis commonly present with arrhythmias and conduction system disorders. Atrial fibrillation is observed in up to 80% of patients at the time of diagnosis, with patients typically maintaining normal heart rates due to concurrent atrioventricular nodal disease. The thromboembolic risk is particularly high in patients with cardiac amyloidosis, and left atrial thrombi have been observed even in the absence of atrial fibrillation. Conduction system diseases are also highly prevalent, often necessitating permanent pacemaker implantation. The use of implantable defibrillators in this population remains controversial. This overview of published data and therapeutic strategies related to arrhythmias and conduction system disorders aims to assist readers in decision-making in complex clinical scenarios.
Glucose levels will be controlled for 3 consecutive nights using insulin pump therapy. Subjects will carry on with their normal conventional insulin pump therapy and will be allowed to freely implement therapeutic adjustments..